Exclusive Summary

• Relaxed competitive environment and exclusive supply potential: With many global pharmas ceasing production of this classic drug, Chinese suppliers offer rare, stable supply capabilities, helping distributors capture an uncrowded long-tail market.
• Absolute low-cost advantage: Compared to newer anesthetics like Sevoflurane, it features an extremely low price threshold, perfectly aligning with budget-constrained public healthcare and centralized procurement needs in low- and middle-income regions like Africa, LATAM, and Southeast Asia.
• Zero equipment switching cost: The 150ml standard packaging seamlessly fits existing basic anesthetic vaporizers globally, allowing direct use without extra training or equipment replacement, minimizing terminal promotion resistance.
• Efficient registration and distribution support: The supplier provides mature registration dossiers (e.g., CTD) to help overseas agents quickly obtain target-country approvals and build highly profitable distribution networks.